From November 13th to 14th, Huang Guo, a member of the Party Group and Deputy Director General of the National Medical Products Administration, led a team to Zhejiang Province for investigative research. They convened the special seminars on the management of APIs, went on-site visiting manufacturers of APIs, and listened to the opinions and suggestions of local drug regulatory authorities and manufacturers of APIs regarding the management of APIs and the holder change.

Huang Guo affirmed the supervision and management of APIs and the development of the industry in Zhejiang Province. He expressed that APIs are a key link in optimizing and strengthening the industrial chain and supply chain of the pharmaceutical industry, pay high attention to and continuously optimize the supervision and management of APIs, actively respond to the demands of the industry's development and constantly stimulate the innovation vitality of the industry. Maintain the problem-oriented approach, draw on international experience, and steadily advance the reform of the API regulatory system in a progressive manner. Strictly uphold safety baseline, enhance quality awareness of enterprises, and promote the high-quality development of the API industry.

Relevant departments of the National Medical Products Administration and relevant officials from the Zhejiang Medical Products Administration participated in the investigative research.